



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

CIN No. L85110KA1987PLC008739

Dated: 09 April, 2019

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Bortezomib for Injection, 3.5mg/vial on 08.04.2019.

Bortezomib for Injection, 3.5mg/vial is a generic equivalent of reference listed drug (RLD), VELCADE used in the treatment of patients with multiple myeloma and Mantle Cell Lymphoma as recommended in the label approved by FDA."

According to IQVIA MAT Q4 2018 data, the US market for Bortezomib for Injection 3.5 mg/vial is approximately US\$ 609 Million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

  
**SUSHIL BAJAJ**

Chief Financial Officer

